Verapamil

Generic Name: Verapamil

Brand Names: Calan, Isoptin, Tarka, Verelan

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₃₈N_₂O_₄

CAS Number: 52-53-9

Unique Ingredient Identifier: CJ0O37KU29

Background: Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes drugs like diltiazem and flunarizine, but is chemically unrelated to other cardioactive medications. Verapamil is administered as a racemic mixture containing equal amounts of the S- and R-enantiomer, each of which is pharmacologically distinct - the S-enantiomer carries approximately 20-fold greater potency than the R-enantiomer, but is metabolized at a higher rate.

Indication: Verapamil is indicated in the treatment of vasopastic (i.e. Prinzmetal's) angina, unstable angina, and chronic stable angina. It is also indicated to treat hypertension, for the prophylaxis of repetitive paroxysmal supraventricular tachycardia, and in combination with digoxin to control ventricular rate in patients with atrial fibrillation or atrial flutter. Given intravenously, it is indicated for the treatment of various supraventricular tachyarrhythmias, including rapid conversion to sinus rhythm in patients with supraventricular tachycardia and for temporary control of ventricular rate in patients with atrial fibrillation or atrial flutter.

Verapamil is commonly used off-label for prophylaxis of cluster headaches.

Associated Conditions: Chronic Stable Angina Pectoris, Cluster Headache, Heart Rate, Hypertension, Paroxysmal Supraventricular Tachycardia (PSVT), Supra-ventricular Tachyarrhythmias, Unstable Angina Pectoris, Vasospastic Angina

Clinical Trials

A Study to Evaluate Whether Verapamil Has an Effect on the Uptake and Elimination of Solifenacin and Tamsulosin When Administered in a Combination Tablet

Phase 1

Completed

Conditions: Drug-Drug Interaction (DDI)
Healthy Subjects

Interventions: Drug: EC905
Drug: verapamil

First Posted Date: 2013-09-17

Last Posted Date: 2014-05-30

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 36

Registration Number: NCT01943487

Locations: 🇫🇷
SGS Aster, Paris, France

Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects

Phase 1

Completed

Conditions: Drug-induced Surface ECG Changes

Interventions: Drug: Placebo
Drug: Ranolazine
Drug: Dofetilide
Drug: Verapamil
Drug: Quinidine sulfate

First Posted Date: 2013-06-10

Last Posted Date: 2018-03-08

Lead Sponsor: Food and Drug Administration (FDA)

Target Recruit Count: 22

Registration Number: NCT01873950

Verapamil vs Steroid to Prevent Keloid Recurrence

Phase 4

Terminated

Conditions: Keloid Scars

Interventions: Drug: Kenalog 10
Drug: Verapamil

First Posted Date: 2012-11-01

Last Posted Date: 2015-06-10

Lead Sponsor: The University of Western Australia

Target Recruit Count: 14

Registration Number: NCT01720056

Locations: 🇦🇺
Royal Perth Hospital, Perth, Western Australia, Australia

Verapamil vs. Sertraline for Vestibular Migraine & Chronic Subjective Dizziness

Phase 1

Completed

Conditions: Vestibular Migraine
Chronic Subjective Dizziness

Interventions: Drug: Sertraline
Drug: Verapamil

First Posted Date: 2012-08-21

Last Posted Date: 2015-08-24

Lead Sponsor: Mayo Clinic

Target Recruit Count: 32

Registration Number: NCT01669304

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Oral Verapamil in Acute Paroxysmal Supra Ventricular Tachycardia(PSVT) Recurrence Control

Phase 4

Completed

Conditions: Paroxysmal Supraventricular Tachycardia

Interventions: Drug: Verapamil

First Posted Date: 2012-08-01

Last Posted Date: 2012-11-14

Lead Sponsor: Tehran University of Medical Sciences

Target Recruit Count: 90

Registration Number: NCT01655316

Rate Control in Atrial Fibrillation

Phase 4

Completed

Conditions: Rapid Ventricular Response Atrial Fibrillation

Interventions: Drug: Metoprolol
Drug: Verapamil
Drug: Propranolol
Drug: Diltiazem

First Posted Date: 2012-08-01

Last Posted Date: 2012-08-01

Lead Sponsor: Tehran University of Medical Sciences

Target Recruit Count: 90

Registration Number: NCT01655303

Locations: 🇮🇷
Rasoul-e-Akram Hospital, Tehran, Iran, Islamic Republic of

Safety, Tolerability, and Efficacy of IA Verapamil in the Treatment of Joint Pain in Subjects With Osteoarthritis of the Knee

Phase 1

Terminated

Conditions: Osteoarthritis of the Knee

Interventions: Drug: Verapamil
Drug: Placebo

First Posted Date: 2012-07-20

Last Posted Date: 2014-09-05

Lead Sponsor: Calosyn Pharma, Inc.

Target Recruit Count: 81

Registration Number: NCT01645709

Verapamil as Therapy for Children and Young Adults With Dravet Syndrome

Phase 2

Completed

Conditions: Dravet Syndrome

Interventions: Drug: Verapamil

First Posted Date: 2012-05-28

Last Posted Date: 2021-04-13

Lead Sponsor: Gillette Children's Specialty Healthcare

Target Recruit Count: 2

Registration Number: NCT01607073

Locations: 🇺🇸
Gillette Children's Specialty Healthcare, Saint Paul, Minnesota, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Children's Memorial Hospital, Chicago, Illinois, United States

and more 1 locations